2018 ANNUAL RESULTS

Sisram Med 復銳醫療科技 (1696.HK)



Enhancing Quality of Life





Disclaimer

This presentation and the accompanying slides (the "Presentation") which have been prepared by Sisram Medical Ltd (the "Company") do not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from this Presentation is expressly excluded.

Certain matters discussed in this presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation, including, amongst others: whether the Company can successfully penetrate new markets and the degree to which the Company gains traction in these new markets; the sustainability of recent growth rates; the anticipation of the growth of certain market segments; the positioning of the Company's products in those segments; the competitive environment; general market conditions and potential impacts on reported results of foreign currency fluctuations relative to the U.S. Dollar. The Company is not responsible for any forward-looking statements and projections made by third parties included in this Presentation.




2018 Annual Results





Our annual results demonstrate a year over year top-line revenue growth of 12.4%, exceeding the industry CAGR*




^{*} Ranging between 9.7%-10.8% according to multiple research sources




Double digit year over year growth across product pillars

By Product Categories




By Geographic Areas







Cash flow & turnover



- Investing activities in 2017 the company invested IPO proceeds in term deposits with original maturity of more than three months
- Financing activities during 2017 the company repaid bank loans at the amount of US\$38.2 million and related party loan and interest at the amount of US\$10.1 million



Net profit adjustments

	2016	2017	2018
PROFIT FOR THE YEAR	8,501	11,049	21,831
Adjusted for:			
Amortization of other intangible assets	4,885	4,827	4,951
Capital Notes imputed interest expenses	4,176	3,079	-
Listing expenses	3,559	2,975	-
Bonus to management and employees relating to IPO	-	3,884	3,992
Interest expense from a related party loan	155	248	-
Due diligence	-	-	616
One-off impact on opening deferred tax from changes in tax rate*	-	114	-
Deduct: deferred tax arising from other intangible assets	(923)	(912)	(596)
One-off VAT adjustment	-	-	1,010
One-off income tax due to encouragement true up	-	-	(2,343)
Total Adjustments	11,852	14,215	7,629
Adjusted Net Profit	20,353	25,264	29,461
Adjusted Net Profit Margin	17.2%	18.5%	19.1%

^{*}Represents the re-evaluation of the deferred tax in the US as a result of Dec 2017 US tax reform legislation.



2018 Annual Results





New product launches **Body contouring Body contouring** / 2018 4 / 2018 **Small areas** Accentuate Hands-free body treatment kit contouring **Body contouring** Anti-aging 11/2018 **PICO CLEAR RESHAPE** The shortest **Ultrasound &** picosecond laser Radiofrequency Beauty platform



M&A – first bird





Alma, a Sisram Medical Company, Announces the Opening of a Direct Operation in Israel Following the Acquisition of its Israeli Distributor

November 20th 2018, Hong Kong, China - Alma, one of the top five global leaders of energy-based medical and aesthetic solutions, today announced it has completed the first step of acquiring its Israeli distributor Nova Medical, extending its business outreach and establishing a direct operation in Israel.

Nova Medical, established in 2003 is one of the largest distributors of Medical Aesthetic technology-based devices in Israel, with net profit before taxation and extraordinary items of approximately HK\$22 million in 2017. Nova Medical serves the widest customer base, from plastic surgeons, dermatologists, general practitioners and beauticians to Medical & Aesthetics clinic chains, SPA and fitness centers.

Upon completion of the acquisition, Alma will hold a 60% stake in Nova Medical. The acquisition is part of Alma's Direct-to-Consumer strategy, outlined in 2017, aimed at maintaining Alma's leading position in the market and strengthening its brand awareness among consumers.





Sisram Med (1696.HK)

Alma, a Sisram Medical Company, Awarded MDSAP Certification, Acknowledging the Highest Quality Standards in the Medical Device Industry

November 30, 2018, Hong Kong, China -- Alma, one of the top five global leaders of energy-based medical and aesthetic solutions, today announced it has received the Medical Device Single Audit Program (MDSAP) certification, following an audit process to upgrade its quality management system certifications.



New venture

Unique and strategic partnership in the Medical Aesthetics market between **IBSA**, a leading pharmaceutical company and – **Alma**, one of the top 5 global leaders in the energy-based medical aesthetic devices industry.

A synergic cooperation with added value on top of extending product distribution in Hong-Kong, India and China.





WHEN TWO GIANTS MEET, THE OUTCOME IS REMARKABLE

Alma and Ibsa invite you to learn from the best!

Please join Profhilo's workshop & hands-on by Dr. Eyal Kramer, and learn about the revolutionary thermally stabilized natural HA for skin remodeling.



Thursday **Nov 15th** 10:00-16:00

Salon Room I & II, Lobby Floor Hyatt Regency Hong Kong 18 Hanoi Road, Tsim Sha Tsui Kowloon, Hong Kong

Agenda:

- Introduction
- Company background & Hydrolift concept
- NAHYCO Technology
- ◆ Science behind PROFHILO
- Treatment Protocol
- Bioremodeling & Patient outcomes
- ◆ Preliminary experience before launch
- Hands-on session







Sisram Medical Expends its Europe Operation, Opening a New Continental Service Facility in Germany

HONG KONG, January 7th, 2019 -- Sisram Medical Ltd ("Sisram" or "the Company") (Hong Kong: 1696), an investment holding company specializing in medical technology for healthcare, today announced the expansion of its business within the medical technology industry at its premises in Nuremberg, Germany.

The new Europe-based holistic service center joins the two existing ones in USA and Israel and will cater all European countries' medical equipment needs including: repair, maintenance and refurbishment.



Alm'a New Campus - Project Initiation

Consolidate three existing facilities into one state-of-the-art, advanced and efficient research, development and production site - an increase of:

- 68% in total floor space
- 92% in production floor

Expected to double the production capacity!






2018 Annual Results





From R&D to production & commercialization



Specializing R&D teams per Energy Source

Laser & Light

Radio Frequency

Ultrasound

Plasma

Clinical research:

Supporting pre-clinical studies performed by third-party institutions

In-house testing

Global compliance team

Production by forecast:

Lead time target of 14 days from order to delivery

Procurement:

Components, subassemblies and other raw materials from 700 suppliers

Semi-finished products:

Production in-house and by subcontractors

Quality control:

Calibration, integration, customization and testing

Direct sales:

To treatment providers and aesthetic chains in the US, Canada, Germany, Austria, India and Israel

Sales to distributors:

~80 distributors globally who purchase treatment systems and on-sell them to treatment providers

Sub-distributors:

Expand and broaden sales channels

Core physicians

Plastic surgeons

Dermatologists

Non-core physicians

Primary care physicians

Obstetricians

Gynecologists

Ear, nose and throat specialists

Aestheticians and other therapists



R&D – solid pillar of our success

- Solid base of Research and Development
- Leading the industry with the shortest time to market: 1-2 years vs. 3-4 years industry standard
- Revolutionizing the industry:
 - **50+** different models of treatment systems
 - **100+** different models of applicators
 - 55 registered patents and 25 patent applications







Prominent member of Fosun Pharma Med-Tech eco-system



- Founded in 1957
- The largest manufacturer and exporter of surgical blades and surgical sutures with needles in China



- Founded in Israel in 1999
- A global innovator of laser, light-based, radio-frequency and ultrasound solutions for the aesthetic and surgical markets

BREAS

- Founded in Sweden in 1991
- A complete and comprehensive line of respiratory medical device
- Powered by Boston engineering



Respiratory Medical Devices





Specializing in R&D, production & distribution of transfusion-related supplies

Dental

FUSHION

- Founded in 2002, advanced dental products & technologies
- One of the leading suppliers of dental equipment and consumables in China

t

CHINDEX

- A leading medical equipment provider
- China Business focusing on surgery, Imaging, oncology, aesthetics & dermatology

Medical Equipment

© 2019 Sisram Medical Ltd. All rights reserved




2018 Annual Results





The B2B Global Medical Aesthetic Market was ~\$9.8B in 2017 and is expected to grow to \$16.4B, with 10.8% CAGR

The **Energy-Based devices** category is the **largest** overall category and will show the **greatest absolute growth**



It is expected that **Asia** will outperform the other regions in terms of growth over the forecast period and will surpass Europe by that time.

Total Medical Aesthetic Market 2017 and 2022 by Region








Well-positioned in the global market

Alma is one of the top 5 global industry leaders and № 1 in the PEOPLE'S REPUBLIC OF CHINA!



^{*} In terms of revenues, source: Medical Insight, 2017



Thank You!

